TSX Venture Exchange approves Advitech's issued and outstanding common shares

Download PDF Copy

Nov 26 2009

NewsGuard 100/100 Score

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that the TSX Venture Exchange Inc. (the "TSX-V") approved the previously announced consolidation of its issued and outstanding common shares on the basis of a ratio of eight pre-Consolidation shares for every one post-Consolidation share (the "Consolidation") and that the common shares of Advitech will be traded on a post-Consolidation basis starting November 26, 2009.

The Consolidation has been completed as part of the previously announced acquisition of all the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by Avrio Ventures Limited Partnership ("Avrio") and SemBioSys Genetics Inc. ("SemBioSys"), the $2,515,000 equity financing with, among others, Agechem L.P Venture ("Agechem") and Avrio, and the redemption of the 58,083,334 pre-Consolidation common share purchase warrants held by AgeChem.

Source:

ADVITECH INC.

Posted in:

Tags: Genetics, Inflammatory Bowel Disease, Insulin, Psoriasis, Wound Healing

Comments (0)

Download PDF Copy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.